SCHEMBL6774632

SCHEMBL6774632

CC(OC(C)(C)CCCC(=O)O)C1CCCC(C)(C)C1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.35
LMNA P02545 1/20 0.32
BLM P54132 1/20 0.32
IDH1 O75874 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3207530 0.85 IDO1 (0.31)
SCHEMBL1396737 0.85 CYP1A2 (0.31) CDC25A
SCHEMBL3198409 0.84
SCHEMBL1396771 0.82 IDO1 (0.31)
Propionic Acid SCHEMBL1044207 0.81
SCHEMBL5674761 0.80
SCHEMBL27237559 0.80 CPB2 (0.30)
SCHEMBL13209034 0.79 IDO1 (0.32)
SCHEMBL31141331 0.79 IDO1 (0.32)
SCHEMBL1396689 0.79 IDO1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197243-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-20 US claimed
EP-4347757-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING Givaudan SA (CH) 2024-04-10 EP claimed
WO-2022234149-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2022-11-10 WO claimed
US-10947483-B2 Encapsulates PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2021-03-16 US claimed
US-10604728-B2 Encapsulates PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2020-03-31 US claimed
US-20200071639-A1 Encapsulates PROCTER & GAMBLE INT OPERATIONS SA (CH) 2020-03-05 US claimed
US-10434485-B2 Compositions comprising encapsulated actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2019-10-08 US claimed
EP-3262148-B1 A SYNERGISTIC PERFUMING COMPOSITION FIRMENICH & CIE (CH) 2018-11-07 EP claimed
US-9878299-B2 Methods for encapsulation of actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2018-01-30 US claimed
EP-3223801-A1 METHODS FOR ENCAPSULATION OF ACTIVES WITHIN DROPLETS AND OTHER COMPARTMENTS The Procter & Gamble Company (US) 2017-10-04 EP claimed
US-9718044-B2 Compositions comprising encapsulated actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2017-08-01 US claimed
US-20170130172-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2017-05-11 US claimed
US-20160304817-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2016-10-20 US claimed
WO-2016085742-A1 METHODS FOR ENCAPSULATION OF ACTIVES WITHIN DROPLETS AND OTHER COMPARTMENTS THE PROCTER & GAMBLE COMPANY (US) 2016-06-02 WO claimed
US-20160145535-A1 Compositions Comprising Encapsulated Actives within Droplets and other Compartments THE PROCTER & GAMBLE COMPANY 2016-05-26 US claimed
US-20160130537-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2016-05-12 US claimed
EP-2806018-A1 ENCAPSULATES The Procter & Gamble Company (US) 2014-11-26 EP claimed
US-20140338134-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2014-11-20 US claimed
US-20140342972-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2014-11-20 US claimed
JP-6072952-A None JP disclosed
US-20260027132-A1 FRAGRANCE COMPOSITIONS AND USE THEREOF FOR IMPROVING SLEEP TAKASAGO INTERNATIONAL CORPORATION (JP) 2026-01-29 US disclosed
US-12453736-B2 Fragrance compositions and use thereof for improving sleep TAKASAGO INTERNATIONAL CORPORATION (JP) 2025-10-28 US disclosed
EP-4446001-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2024-10-16 EP disclosed
EP-4407019-A1 BIODEGRADABLE PERFUME COMPOSITION Givaudan SA (CH) 2024-07-31 EP disclosed
US-20240197243-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-20 US disclosed
EP-4347757-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING Givaudan SA (CH) 2024-04-10 EP disclosed
US-20240050917-A1 PROCESS FOR PREPARING POLYESTER MICROCAPSULES FIRMENICH SA (CH) 2024-02-15 US disclosed
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-02-08 US disclosed
US-11820961-B2 Musk compositions and methods of use thereof TAKASAGO INTERNATIONAL CORPORATION (JP) 2023-11-21 US disclosed
EP-3313361-B1 MUSK COMPOSITION AND METHODS OF USE THEREOF TAKASAGO PERFUMERY CO LTD (JP) 2023-09-13 EP disclosed
WO-2022234149-A1 FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2022-11-10 WO disclosed
EP-4039244-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2022-08-10 EP disclosed
US-20220220412-A1 MUSK COMPOSITIONS AND METHODS OF USE THEREOF TAKASAGO INTERNATIONAL CORPORATION (USA) (US) 2022-07-14 US disclosed
EP-3313362-B1 MUSK COMPOSITIONS AND METHODS OF USE THEREOF TAKASAGO PERFUMERY CO LTD (JP) 2022-02-09 EP disclosed
US-11236288-B2 Fragrance materials TAKASAGO INTERNATIONAL CORPORATION (JP) 2022-02-01 US disclosed
US-20210230504-A1 FRAGRANCE MATERIALS TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-07-29 US disclosed
US-20210198229-A1 FRAGRANCE AND FLAVOR MATERIALS FROM 1-(2-HYDROXY-4-METHYLCYCLOHEXYL)-ETHANONE TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-07-01 US disclosed
US-10947483-B2 Encapsulates PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2021-03-16 US disclosed
US-20210008082-A1 FRAGRANCE COMPOSITIONS AND USE THEREOF FOR IMPROVING SLEEP TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-01-14 US disclosed
US-20200407301-A1 FRAGRANCE AND FLAVOR MATERIALS DERIVED FROM 1-(4-METHYLCYCLOHEX-1-EN-1-YL)ETHAN-1-ONE TAKASAGO INTERNATIONAL CORPORATION (JP) 2020-12-31 US disclosed
US-10604728-B2 Encapsulates PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2020-03-31 US disclosed
US-20200078758-A1 Methods and Systems for Forming Microcapsules THE PROCTER & GAMBLE COMPANY 2020-03-12 US disclosed
US-20200078757-A1 Methods and Systems for Forming Microcapsules THE PROCTER & GAMBLE COMPANY 2020-03-12 US disclosed
US-20200078759-A1 Methods and Systems for Forming Microcapsules THE PROCTER & GAMBLE COMPANY 2020-03-12 US disclosed
US-20190344237-A1 Compositions Comprising Encapsulated Actives within Droplets and other Compartments PROCTER & GAMBLE (US) 2019-11-14 US disclosed
US-10434485-B2 Compositions comprising encapsulated actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2019-10-08 US disclosed
US-9878299-B2 Methods for encapsulation of actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2018-01-30 US disclosed
US-20170296996-A1 Compositions Comprising Encapsulated Actives within Droplets and other Compartments PROCTER & GAMBLE (US) 2017-10-19 US disclosed
US-9718044-B2 Compositions comprising encapsulated actives within droplets and other compartments THE PROCTER & GAMBLE COMPANY (US) 2017-08-01 US disclosed
US-20170130172-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2017-05-11 US disclosed
US-20160304817-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2016-10-20 US disclosed
US-20160144329-A1 Systems for Encapsulation of Actives within Droplets and other Compartments THE PROCTER & GAMBLE COMPANY 2016-05-26 US disclosed
US-20160144330-A1 Methods for Encapsulation of Actives within Droplets and other Compartments THE PROCTER & GAMBLE COMPANY 2016-05-26 US disclosed
US-20160145535-A1 Compositions Comprising Encapsulated Actives within Droplets and other Compartments THE PROCTER & GAMBLE COMPANY 2016-05-26 US disclosed
US-20160130537-A1 ENCAPSULATES PROCTER & GAMBLE (US) 2016-05-12 US disclosed
EP-2806018-A1 ENCAPSULATES The Procter & Gamble Company (US) 2014-11-26 EP disclosed
US-20140342972-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2014-11-20 US disclosed
US-20140338134-A1 ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2014-11-20 US disclosed
EP-2799864-A1 Method to evaluate fragrance compositions The Procter and Gamble Company (US) 2014-11-05 EP disclosed
EP-2799863-A1 Method to evaluate fragrance compositions The Procter and Gamble Company (US) 2014-11-05 EP disclosed
US-20140135402-A1 CYCLODODECADIENONE DERIVATIVES AS PERFUMING INGREDIENTS FIRMENICH SA (CH) 2014-05-15 US disclosed
US-6734158-B2 USING 6-METHYL-7-OXA-7-THIA-4AZASPIRO(4.4)NONANE FIRMENICH SA (CH) 2004-05-11 US disclosed
JP-H0672952-A IMPROVEMENT, EMPHASIS, IMPARTION OR MODIFICATION OF FRAGRANCE CHARACTERISTIC OF NEW ESTER COMPOUND, PERFUMERY COMPOSITION AND ODORIZING ARTICLE AND PRODUCTION OF ODORIZING COMPOSITION AND ARTICLE AND NEW COMPOUND AND THEIR INTERMEDIATES FIRMENICH SA 1994-03-15 JP disclosed
JP-H0672952-A IMPROVEMENT, EMPHASIS, IMPARTION OR MODIFICATION OF FRAGRANCE CHARACTERISTIC OF NEW ESTER COMPOUND, PERFUMERY COMPOSITION AND ODORIZING ARTICLE AND PRODUCTION OF ODORIZING COMPOSITION AND ARTICLE AND NEW COMPOUND AND THEIR INTERMEDIATES FIRMENICH SA 1994-03-15 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071639-A1 Encapsulates LIPA, TTPA, CHMP4B CDC25A 4031/4885LMNA 1015/4885BLM 1662/4885
US-10947483-B2 Encapsulates LIPA, TTPA, CHMP4B CDC25A 4031/4885LMNA 1015/4885BLM 1662/4885
US-20210198229-A1 FRAGRANCE AND FLAVOR MATERIALS FROM 1-(2-HYDROXY-4-METHYLCYCLOHEXYL)-ETHANONE TAS2R5, TAS2R50, TAS2R20 CDC25A 3145/4885LMNA 3583/4885BLM 4173/4885
US-20240050917-A1 PROCESS FOR PREPARING POLYESTER MICROCAPSULES CHMP4B, EXOSC9, F5 CDC25A 1266/4885LMNA 2020/4885BLM 3637/4885
US-20200407301-A1 FRAGRANCE AND FLAVOR MATERIALS DERIVED FROM 1-(4-METHYLCYCLOHEX-1-EN-1-YL)ETHAN-1-ONE TAS2R1, TAS1R1, TAS2R50 CDC25A 2510/4885LMNA 2778/4885BLM 4511/4885
US-20260027132-A1 FRAGRANCE COMPOSITIONS AND USE THEREOF FOR IMPROVING SLEEP B2M, PER2, CHRM2 CDC25A 1867/4885LMNA 761/4885BLM 3401/4885
US-20220220412-A1 MUSK COMPOSITIONS AND METHODS OF USE THEREOF MUSK, MSI2, SYMPK CDC25A 935/4885LMNA 1587/4885BLM 1701/4885
US-11820961-B2 Musk compositions and methods of use thereof MUSK, MSI2, SYMPK CDC25A 935/4885LMNA 1587/4885BLM 1701/4885
US-20240041752-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AOX1, TYR, OCIAD1 CDC25A 2052/4885LMNA 3936/4885BLM 1809/4885
US-20140135402-A1 CYCLODODECADIENONE DERIVATIVES AS PERFUMING INGREDIENTS CBR3, HPGD, CFD CDC25A 1415/4885LMNA 2260/4885BLM 3452/4885
US-11236288-B2 Fragrance materials NISCH, TRPA1, FAAH2 CDC25A 3994/4885LMNA 3036/4885BLM 2707/4885
US-20210230504-A1 FRAGRANCE MATERIALS NISCH, TRPA1, FAAH2 CDC25A 3994/4885LMNA 3036/4885BLM 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.